DECEMBER - JANUARYLIFE SCIENCES REVIEW5CXO INSIGHTSCXO INSIGHTSFEATURED COMPANy20Ozgur Akbulut, Director, Global Divestments and Contract Manufacturing Lead, Takeda [NYSE: TAK]How CMOs/CDMOs can Add Value for Pharma Companies15Araz Raoof, Senior Vice President, Global Drug Discovery & External Innovation, Ferring PharmaceuticalsDiscovering the Medicines of the Future22Roman Mathaes,Head of Pharmaceutical Services &Cristina Grigore,Technical Proposals Manager,LonzaPartnering with a CDMO for successful late phase biologic drug product development and launch25Kimberly Paris, SVP & Chief Compliance Officer, Quotient SciencesThe Ever-Evolving Challenges in Drug Development and Manufacturing28Hua Gong, M.D., Ph.D., SVP, Global Head of Translational Medicine and Clinical Biomarker, Zai LabAccelerating drug development of novel targeted therapies through histology-agnostic oncology clinical trials29Dr. Kim M. Bonner, BSc (Hons) VMD Ph.D., Executive Director, Clinical Development, Syneos HealthThe Challenging Aspects of Developing AI/ML-Based Diagnostic Pathology PlatformsCurtis Health Caps (CHC)Anna Michalak, Ph.D., Board Member,Chief Product Development & Quality Officer18IN EUROPE - 2022TOP 10CDMOsBIOPHARMACEUTICALS: THE GAME CHANGER IN MODERN DAY DRUG DISCOVERY
< Page 4 | Page 6 >